Trx mediates the resistance to tamoxifen therapy in breast cancer cells through changes in H2O2 production and modulation of estrogen-dependent and estrogen-independent redox-sensitive signaling pathways (Penney and Roy, 2013). This evidence concerns the gene TXN and breast carcinoma.